JW (Cayman) Therapeutics Co. Ltd (JWCTF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

jwctf · pe ratio · data through Jun 9, 2026

Core PE Ratio Metrics

Trailing 12 months · TTM

Insufficient PE history data (fewer than 3 valid fiscal years).

PE Ratio vs Peers

Biotechnology · 3 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
JW (Cayman) Therapeutics Co. LtdYou JWCTF	$148M	N/A	—	—
Brii Biosciences Limited BRIBF	$167M	N/A	—	-$0.30
Botanix Pharmaceuticals Limited BXPHF	$51M	N/A	—	-$0.05
Innate Pharma S.A. IPHYF	$211M	N/A	—	-$0.55

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for JW (Cayman) Therapeutics Co. Ltd (JWCTF) measures how much investors pay for each dollar of the company's trailing earnings. JWCTF's current PE ratio of N/A is calculated by dividing its stock price of $0.36 by its TTM earnings per share of —.

PE Ratio = Stock Price ÷ EPS (TTM)

= $0.36 ÷ — = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

JWCTF pe ratio · 6 questions

JWCTF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.36 and TTM EPS of —. Data sourced from Financial Modeling Prep via JWCTF's SEC 10-K and 10-Q filings.

JWCTF PE ratioWhat is JWCTF PE ratioCurrent PE ratio of JWCTFJWCTF PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · JW (Cayman) Therapeutics Co. Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09